Captrust Financial Advisors Purchases Shares of 11,073 ImmunityBio, Inc. (NASDAQ:IBRX)

Captrust Financial Advisors purchased a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,073 shares of the company’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Algert Global LLC bought a new position in ImmunityBio during the second quarter valued at approximately $86,000. Dimensional Fund Advisors LP bought a new position in shares of ImmunityBio in the second quarter worth approximately $105,000. CIBC Asset Management Inc bought a new position in shares of ImmunityBio in the second quarter worth approximately $118,000. Mercer Global Advisors Inc. ADV bought a new position in shares of ImmunityBio in the second quarter worth approximately $126,000. Finally, Victory Capital Management Inc. grew its holdings in shares of ImmunityBio by 16.0% in the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock worth $126,000 after purchasing an additional 2,746 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on IBRX. EF Hutton Acquisition Co. I upgraded shares of ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of ImmunityBio in a report on Thursday, November 21st. Finally, Piper Sandler dropped their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research note on Monday, August 19th.

ImmunityBio Stock Up 6.6 %

Shares of IBRX stock opened at $3.06 on Tuesday. The stock has a fifty day moving average of $4.55 and a 200 day moving average of $4.82. ImmunityBio, Inc. has a 52 week low of $2.82 and a 52 week high of $10.53. The firm has a market capitalization of $2.13 billion, a price-to-earnings ratio of -3.33 and a beta of 0.86.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.